Vaccine Funding Support

Operation Warp Speed All of the investments under Operation Warp Speed include investment into manufacturing capabilities. On March 30th HHS announced $456 million in funds for Johnson & Johnson’s candidate…

Continue Reading Vaccine Funding Support

Promising Vaccine Candidates

Novavax – NVX-CoV2373 Uses SARS-CoV-2 recombinant spike protein nanoparticle with proprietary saponin-based adjuvant Matrix-M. Currently in phase 1/2 clinical trials. More at: https://clinicaltrials.gov/ct2/show/NCT04368988 Moderna – mRNA-1273 Messenger-RNA based vaccine –…

Continue Reading Promising Vaccine Candidates

Research of note

Hydroxychloroquine benefits against COVID-19 A study at University of Minnesota claims that hydroxychloroquine offers no benefits to patients with COVID-19. The death rates in the group treated with hydroxychloroquine and…

Continue Reading Research of note

Treatment for Covid-19

A preliminary report suggests that dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support. This paper has…

Continue Reading Treatment for Covid-19